

Yellow Fever: Factors Associated with Death in a Hospital of Reference in Infectious Diseases, São Paulo, Brazil, 2018

Ana Freitas Ribeiro,^{1,2*} Roberta Figueiredo Cavalin,¹ Jamal Muhamad Abdul Hamid Suleiman,¹ Jessica Alves da Costa,¹ Marileide Januaria de Vasconcelos,¹ Ceila Maria Sant'Ana Málaque,¹ and Jaques Sztajnbock¹

¹Institute of Infectology Emilio Ribas, São Paulo, Brazil; ²Nove de Julho University, São Paulo, Brazil

Abstract. Faced with the reemergence of yellow fever (YF) in the metropolitan region of São Paulo, Brazil, we developed a retrospective study to describe the cases of YF attended at the Institute of Infectology Emilio Ribas from January to March 2018 and analyze the factors associated with death, from the information obtained in the hospital epidemiological investigation. A total of 72 cases of sylvatic YF were confirmed, with 21 deaths (29.2% lethality rate). Cases were concentrated in males (80.6%) and in the age group of 30 to 59 years (56.9%). Two logistic regression models were performed, with continuous variables adjusted for the time between onset of symptoms and hospitalization. The first model indicated age (odds ratios_{adjusted} [OR_{adj}]: 1.038; CI 95%: 1.008–1.212), aspartate aminotransferase (AST) (OR_{adj}: 1.038; CI 95%: 1.005–1.072), and creatinine (OR_{adj}: 2.343; CI 95%: 1.205–4.553) were independent factors associated with mortality. The second model indicated age (OR_{adj}: 1.136; CI 95%: 1.013–1.275), alanine aminotransferase (ALT) (OR_{adj}: 1.118; CI 95%: 1.018–1.228), and creatinine (OR_{adj}: 2.835; CI 95%: 1.352–5.941). The risk of death in the model with continuous variables was calculated from the increase of 1 year (age), 1 mg/dL (creatinine), and 100 U/L for AST and ALT. Another logistic regression analysis with dichotomous variables indicated AST > 1,841 IU/L (OR_{adj}: 12.92; CI 95%: 1.50–111.37) and creatinine > 1.2 mg/dL (OR_{adj}: 81.47; CI 95%: 11.33–585.71) as independent factors associated with death. These results may contribute to the appropriate clinical management of patients with YF in health-care services and improve the response to outbreaks and public health emergencies.

INTRODUCTION

Yellow fever (YF) is an infectious disease endemic in the tropical forests of America and Africa, transmitted to humans after bites from hematophagous insects of the Culicidae family, especially the genus *Aedes* and *Haemagogus*. The YF virus belongs to the *Flavivirus* genus of the *Flaviviridae* family, being a single-stranded RNA virus.¹ The disease is endemic in 44 countries in Africa and the Americas. In West Africa, the risk of epidemics has been declining following large-scale vaccination campaigns, where millions of people were vaccinated in a short period of time.²

The last record of urban YF in Brazil occurred in 1942, although there have been sporadic reports of human cases of sylvatic YF, especially in the Amazon region in unvaccinated individuals.³ From 1980 to 2016, 797 cases of sylvatic YF occurred in Brazil, with increased circulation of the virus from 1998 to the central west, southeast, and south regions.⁴

Yellow fever is a mandatory reportable disease in Brazil, and the definition of a suspected case consists of an individual with fever (< 7 days of onset), accompanied by jaundice or hemorrhagic manifestations, who had been in risk areas for YF and not been previously vaccinated.³ In 2009, a study analyzed 28 confirmed cases of sylvatic YF in the state of São Paulo, demonstrating that only 50% met the case definition.⁵

According to a report from the Ministry of Health, from December 2016 to May 13, 2017, 792 human cases of sylvatic YF and 274 deaths were confirmed in the country (34.5%), with 487 cases in Minas Gerais state (61.4%), 260 cases in Espírito Santo state (32.8%), and 20 cases in São Paulo state (4.1%). In this period, 642 cases were confirmed in nonhuman primates (NHP).⁶ From July 2017 to May 2018, 1,266 human

cases of sylvatic YF were confirmed and 415 deaths (lethality rate 32.8%), and 752 were confirmed in NHP. Most human cases occurred in the southeast region: 520 cases and 177 deaths in Minas Gerais (lethality rate 34.0%), 516 cases and 163 deaths in São Paulo (lethality rate 31.6%), and 223 cases and 73 deaths in Rio de Janeiro (lethality rate 32.7%).⁷

Yellow fever is an acute viral infectious disease with variable severity and may manifest as oligosymptomatic forms to fulminant presentations (5–10%), with a high lethality. A study analyzing data from the YF epidemic in Gambia showed that for each severe case, there were 12 unapparent cases.⁸ Another study in Maranhao, Brazil, found a proportion of asymptomatic cases equal to 45.2%.⁹

The YF vaccine is the main control measure and is presently administered in Brazil as a single dose from 9 months or older, for residents or travelers to areas where vaccination is recommended. In response to the reemergence of the disease in the metropolitan region of São Paulo, the São Paulo State Department of Health defined an algorithm for YF cases, with participation of the Institute of Infectology Emilio Ribas (IIER). Thus, the objective of this study was to describe the clinical, epidemiological, and laboratory characteristics of confirmed YF cases attended in the IIER and to evaluate the factors associated with death from January to March 2018.

MATERIALS AND METHODS

This is a retrospective study with data from the Epidemiological Investigation Files (EIF) of the National Disease Notification System collected in the routine of epidemiological investigation of the suspected cases of YF attended in the IIER. The IIER is a reference hospital for infectious diseases in São Paulo state, with 199 beds, of which 12 are intensive care unit (ICU) beds. The Epidemiology Service performs an active search daily of all patients attended at the hospital to investigate cases requiring a mandatory report. The information was collected by interviews with patients, by evaluation of

*Address correspondence to Ana Freitas Ribeiro, Institute of Infectology Emilio Ribas, 165 Avenida Doutor Arnaldo, São Paulo 01246-900, Brazil. E-mail: anafreibeiro@uol.com.br

medical records, and from results of laboratory tests during patient admission.

The case definitions followed Brazil’s epidemiological surveillance standards (3).³ This study included the cases of sylvatic YF attended in the IIER, confirmed by real-time polymerase chain reaction (RT-PCR) and/or positive serology (IgM), carried out in the Adolfo Lutz Institute. Samples of serum or tissue fragments are subjected to RNA extraction by commercial kits according to the manufacturers’ guidelines. Next, the RNA extracted is subjected to the RT-PCR protocol, using primers and probes specific for amplification of RNA segments of the YF virus. Initially, the extracted RNA is submitted to the protocol that amplifies a noncoding region of the 5’ end of the virus, being conserved among the different strains. This protocol can detect both the wild-type virus genome and the vaccine-virus genome.¹⁰ The positive samples in the first reaction are submitted to a reaction for differentiation between wild and vaccine viruses. In this second stage, a new RT-PCR is performed, which detects only the vaccine virus.¹¹ Therefore, samples with a positive result in the first reaction and negative result in the second reaction are considered positive for wild virus. Samples positive in both reactions are considered positive for vaccine virus.

The cases were classified according to severity, based on the algorithm of the Department of Health of Minas Gerais state: patients with aspartate aminotransferase (AST) > 2,000 U/L and/or creatinine > 2 mg/dL and/or the international normalized ratio (INR) > 1.5 seconds and/or total bilirubin (TB) > 5 mg/dL.¹²

Spatial distribution of the cases was presented according to the probable municipalities of infection, in a thematic map created in Quantum Geographic Information System (version 2.16.1; QGIS, Community-Team). The associations between qualitative variables were analyzed by Pearson’s χ^2 test (or Fisher’s exact test, if necessary), and for quantitative variables,

Student’s *t*- or Mann–Whitney test was used, according to the data distribution. The linear association between the continuous variables was verified by the Spearman correlation coefficient, and the factors associated with death were assessed by logistic regression, resulting in adjusted and unadjusted odds ratios (OR), with respective confidence intervals (CI 95%). We performed two logistic regressions models to evaluate the risks associated with death. The first model considered the continuous variables with variations of one unit; every 100 units for AST, alanine aminotransferase (ALT), and leukocytes; or every 1,000 units for platelets, and the second model transformed these variables into nominal values with cutoff points. The significance level adopted was 5%, and statistical analyses were performed in Statistical Package for Social Science (version 25; SPSS, Chicago, IL). The study used information obtained from hospital epidemiological surveillance, and the data use was approved by the Ethics Committee of IIER (Protocol 024329/2018).

RESULTS

From January to March 2018, 99 suspected cases of YF were attended at IIER and reported by the Epidemiology Service. Seventy-two cases of sylvatic YF (72.7%) were confirmed, 25 cases were discarded (25.3%), and two mild cases were inconclusive (2.0%)—one case without a sample collection and one case with negative IgM serology in a sample collected 48 days after the onset of symptoms. The first confirmed case presented a symptom onset in epidemiological week (EW) 52 on December 26, 2017, and the last included a case in EW 12 on March 23, 2018. Cases were concentrated in January, with a peak in weeks 2 and 3 (January 7–20), according to Figure 1.

All discarded cases (25) presented negative RT-PCR and/or negative IgM results for YF in samples collected at an




FIGURE 1. Number of suspected cases of yellow fever, according to laboratory confirmation and epidemiological week of onset of symptoms, Institute of Infectology Emilio Ribas, 2018.

TABLE 1

Number of confirmed cases of sylvatic yellow fever, according to evolution and sociodemographic variables, Institute of Infectology Emilio Ribas, 2018

Sociodemographic characteristics	Clinical evolution			P-value
	Total	Cure	Death	
	No. (%)	No. (%)	No. (%)	
Gender				
Female	14 (19.4)	11 (21.6)	3 (14.3)	0.744*
Male	58 (80.6)	40 (78.4)	18 (85.7)	
Age range (years)				
11–29	16 (22.2)	15 (29.4)	1 (4.8)	0.004*
30–59	41 (56.9)	30 (58.8)	11 (52.4)	
≥ 60	15 (20.8)	6 (11.8)	9 (42.9)	
Median age (min†–max‡) (years)	41.5 (11–86)	37 (11–68)	55 (21–86)	< 0.001§
Race/skin color				
White	47 (65.3)	32 (62.7)	15 (71.4)	0.482
Nonwhite	25 (34.7)	19 (37.3)	6 (28.6)	
Years of study¶				
Up to 8	30 (44.1)	20 (39.2)	10 (58.8)	0.159
More than 8	38 (55.9)	31 (60.8)	7 (41.2)	

* Fisher's exact test.

† Minimum value.

‡ Maximum value.

§ Student's *t*-test.

|| Pearson's χ^2 test.

¶ Four cases without information.

discharge, the median was 4 days (range 1–57 days) for the deaths and 6 days for the cures (range 1–36 days) ($P = 0.072$).

Considering the 69 cases who reported YF vaccine status (95.8%), nine cases were vaccinated before the onset of symptoms (13.0%), with one case in a 66-year-old woman vaccinated 30 days before the onset of symptoms, one in a 24-year-old woman vaccinated 100 days before disease

onset, and three cases (4.3%) vaccinated 1 to 3 days, three cases (4.3%) 4 to 10 days, and one case (1.4%) 11 days before presenting symptoms. The majority of these cases evolved to cure (98.5%), except for one case vaccinated 3 days before symptom onset. Information about the clinical and epidemiological characteristics of cases is presented in Table 2.

TABLE 2

Number of cases of sylvatic YF, according to evolution and clinical and epidemiological variables, Institute of Infectology Emilio Ribas, 2018

Clinical and epidemiological characteristics	Clinical evolution						P-value
	Total		Cure		Death		
	No. of available information (%)		No. positive (%)		No. positive (%)		
Symptoms and signs							
Fever	71	98.6	51	100.0	20	100.0	1.000*
Myalgia	67	93.1	42	82.4	15	93.8	0.430*
Nausea	65	84.6	37	83.3	14	88.2	1.000*
Headache	67	93.1	37	72.5	14	87.5	0.320*
Vomiting	64	88.9	34	70.8	12	75.0	1.000*
Abdominal pain	70	97.2	25	50.0	16	80.0	0.031*
Jaundice (total bilirubin ≥ 2.0 mg/dL)	71	98.6	14	28.0	19	90.5	< 0.001*
Chills	57	79.1	23	52.3	05	38.5	0.530*
Back pain	29	40.3	20	95.2	07	87.5	0.482*
Diarrhea	63	87.5	10	20.8	04	26.6	0.725*
Hemorrhagic signs	72	100.0	04	7.8	04	23.5	0.219*
Presence of comorbidities†	70	97.2	12	24.0	10	50.5	0.047*
< 60 years	55	96.5	07	12.7	05	9.1	0.048*
≥ 60 years	15	100.0	05	33.3	05	33.3	0.580*
History of alcoholism and/or drug use†	72	100.0	14	27.5	11	52.4	0.058*
Previous YF vaccination	69	95.8	08	15.7	01	5.5	0.428*
Median number of days from disease onset to hospital admission (min‡–max§)	5 (0–18)		5 (1–18)		4 (0–11)		0.272
Median number of hospitalization days (min‡–max§)	6 (0–57)		6 (1–36)		4 (1–57)		0.072

YF = yellow fever.

* Fisher's exact test.

† Information recorded in the medical chart.

‡ Minimum value.

§ Maximum value.

|| Mann-Whitney test.

TABLE 3
Number of cases of sylvatic yellow fever, according to evolution and laboratory results, Institute of Infectology Emilio Ribas, 2018

Laboratory results	No. of available laboratory results (%)	Clinical evolution		P-value*
		Cure	Death	
		Median (min†–max‡)	Median (min†–max‡)	
Leukocytes (cells/mm)	71 (98.6)	3,050 (1,000–8,300)	6,000 (1,500–27,300)	0.001
Platelets (cells/mm ³)	71 (98.6)	110,000 (30,000–237,000)	75,000 (21,000–179,000)	0.022
Total bilirubin (mg/dL)	71 (98.6)	1.1 (0.3–11.8)	6.2 (0.5–14.6)	< 0.001
Direct bilirubin (mg/dL)	69 (95.8)	0.7 (0.2–9.5)	5.2 (0.3–10)	< 0.001
Aspartate aminotransferase (U/L)	71 (98.6)	1,357 (28–12,010)	8,966 (839–36,520)	< 0.001
Alanine aminotransferase (U/L)	71 (98.6)	1,420.5 (22–6,249)	3,320 (908–10,100)	< 0.001
International normalized ratio (seconds)	71 (98.6)	1.2 (0.9–13.3)	2.4 (1–15)	< 0.001
Urea (mg/dL)	70 (97.2)	28 (14–155)	146 (31–409)	< 0.001
Creatinine (mg/dL)	71 (98.6)	0.9 (0.6–5.6)	5.8 (0.7–14.5)	< 0.001
Creatine phosphokinase (U/L)	67 (93.0)	193 (22–6,151)	796 (64–15,262)	< 0.001

* Mann-Whitney test.

† Minimum value.

‡ Maximum value.

Comparing cases who evolved to cure and death, the findings from the laboratory tests at the time of hospital admission indicate that patients who died presented lower median platelet count and higher median levels of white blood cell count, AST, ALT, TB, direct bilirubin (DB), INR, urea, creatinine, and creatine phosphokinase (CPK), with statistical significance (Table 3).

The correlation of laboratory tests, evaluated by the Spearman coefficient, indicated a strong to moderate correlation between TB and DB; AST and ALT; AST, ALT, and INR; and urea and creatinine. Logistic regression was used to

associated with mortality in model 2. The risk of death increases by 14% for each one year increase in age. In relation to ALT, the increase is 11.8% for each growth of 100 units, whereas the creatinine for each unit increases the risk of death by 183%, according to model 2 (Table 4).

From the models described, it was possible to calculate the probability (*P*) of death, given age; the values of AST, creatinine, and TOSH; or age, ALT, creatinine at hospital admission, and TOSH. The equations from the logistic regression models for quantitative variations in one unit of the variables are shown as follows:

Model 1: Age, AST, creatinine, and TOSH

$$\text{Probability (death)} = \frac{\exp(\beta_0 + \beta_1 \times \text{AST} + \beta_2 \times \text{creatinine} + \beta_3 \times \text{age} + \beta_4 \times \text{TOSH})}{1 + \exp(\beta_0 + \beta_1 \times \text{AST} + \beta_2 \times \text{creatinine} + \beta_3 \times \text{age} + \beta_4 \times \text{TOSH})}$$

$$\text{Probability (death)} = \frac{\exp(8.447 + 0.000374 \times \text{AST} + 0.851 \times \text{creatinine} + 0.100 \times \text{age} - 0.181 \times \text{TOSH})}{1 + \exp(-8.447 + 0.000374 \times \text{AST} + 0.851 \times \text{creatinine} + 0.100 \times \text{age} - 0.181 \times \text{TOSH})}$$

Model 2: Age, ALT, creatinine, and TOSH

$$\text{Probability (death)} = \frac{\exp(\beta_0 + \beta_1 \times \text{ALT} + \beta_2 \times \text{creatinine} + \beta_3 \times \text{age} + \beta_4 \times \text{TOSH})}{1 + \exp(\beta_0 + \beta_1 \times \text{ALT} + \beta_2 \times \text{creatinine} + \beta_3 \times \text{age} + \beta_4 \times \text{TOSH})}$$

$$\text{Probability (death)} = \frac{\exp(11.031 + 0.00111 \times \text{ALT} + 1.042 \times \text{creatinine} + 0.128 \times \text{age} - 0.250 \times \text{TOSH})}{1 + \exp(-11.031 + 0.00111 \times \text{ALT} + 1.042 \times \text{creatinine} + 0.128 \times \text{age} - 0.250 \times \text{TOSH})}$$

identify factors associated with death. Unadjusted and adjusted OR were calculated and are presented in Table 4.

Excluding CPK, all other measures of laboratory tests were associated with mortality in the study group. Considering the collinearity between some of the variables, we constructed two regression models. In model 1, age, AST, and creatinine values were independent factors associated with mortality (both with $P < 0.05$). The models were adjusted for the time between onset of symptoms and hospitalization (TOSH). The risk of death increases by 10% for each 1 year increase in age. In relation to AST, the increase is 3.8% for each growth of 100 units, whereas the creatinine for each unit increases the risk of death by 134%, according to model 1 (Table 4). Age and values of ALT and creatinine were independent factors

Based on the equations (models 1 and 2), it was possible to calculate the probability of death due to YF (in percentages), fixing the age at 40 years or 60 years and also the TOSH at 5 days, presented in Figures 3 and 4 for specific values of creatinine and AST, and creatinine and ALT, respectively.

The graphs presented in Figures 3 and 4 indicate a remarkable increase in the probability of death due to YF at age 60 years when compared with subjects aged 40 years, and also a progressive increase related to ALT, AST, and creatinine blood values. For example, a 40-year-old individual with creatinine = 2.4 mg/dL and ALT = 3,000 U/L at hospital admission would have a 21.1% probability of death, whereas an individual aged 60 years and with the same laboratory results at admission would have a probability of dying equal to 77.5%.

TABLE 4
Factors related to mortality in patients with yellow fever, Institute of Infectology Emilio Ribas, 2018

Laboratory results	OR _{unadjusted} (CI 95%)	P-value	Model 1*		Model 2†	
			OR _{adjusted} (CI 95%)	P-value	OR _{adjusted} (CI 95%)	P-value
Age (one year)	1.078 (1.034–1.123)	0.001	1.105 (1.008–1.212)	0.033	1,136 (1,013–1,275)	0.030
Leukocytes (cells/mm ³) (100 U/L)	1.044 (1.018–1.071)	0.001				
Platelets (cells/mm ³) (1,000 U/L)	0.996 (0.997–0.999)	0.030				
Total bilirubin (mg/dL)	1.455 (1.193–1.773)	< 0.001				
Direct bilirubin (mg/dL)	1.521 (1.216–1.902)	< 0.001				
Aspartate aminotransferase (U/L) (100 U/L)	1.043 (1.021–1.066)	< 0.001	1.038 (1.005–1.072)	0.023		
Alanine aminotransferase (U/L) (100 U/L)	1.086 (1.039–1.136)	< 0.001			1.118 (1.018–1.228)	0.020
International normalized ratio (seconds)	1.873 (1.108–3.165)	0.019				
Urea (mg/dL)	1.040 (1.021–1.058)	< 0.001				
Creatinine (mg/dL)	2.833 (1.570–5.111)	0.001	2.343 (1.205–4.553)	0.012	2.835 (1.352–5.941)	0.006
Creatine phosphokinase (U/L)	1.001 (1.00–1.001)	0.113				
Time between onset of symptoms and hospital admission (days)	0.903 (0.767–1.062)	0.216	0.885 (0.546–1.276)	0.404	0.779 (0.449–1,218)	0.273

OR = odds ratio.

* Hosmer and Lemeshow test = 0.907.

† Hosmer and Lemeshow test = 0.998.

When analyzing the probability with the same creatinine value (2.4 mg/dL), but considering an AST value equal to 3,000 U/L, a 40-year-old patient would have a 10.2% chance of death, whereas a 60-year-old individual would have a 45.7% probability of death.

The quantitative variables were also categorized as dichotomous according to the median of general values for the construction of another logistic regression model, which indicated AST > 1,841 U/L (odds ratios_{adjusted}[OR_{adj}]: 12.92; CI 95%: 1.50–111.37) and creatinine > 1.2 mg/dL (OR_{adj}: 81.47; CI 95%: 11.33–585.71) as factors independently associated with death (Table 5).

DISCUSSION

The present study described the cases of sylvatic YF treated at a reference hospital for infectious diseases in the state of São Paulo. The confirmed cases had a PPI in sylvatic areas, especially in the metropolitan region of São Paulo, with particular emphasis on the municipality of Mairipora, whose rural area corresponds to 62.9% of the territory and 80.1% of the total area is within the Law of Protection of Watersheds,¹³ with abundant vegetation and environmental conditions favorable to the existence of vectors and nonhuman hosts. In

1999 and 2000, during the sylvatic YF epidemic which occurred in the central-western region of the country, there were also cases in other areas, such as the southeast, where there had been no record of virus circulation for more than four decades. In the following year, the virus was also identified in the southern region. Factors related to this expansion include increased rainfall, wild vector proliferation, vector longevity, virulence of the virus, and large numbers of the population being susceptible. Another important factor would be contact of unvaccinated humans in environments with NHP, motivated by hunting, thus increasing the probability of transmission of the sylvatic cycle.¹⁴ A study was conducted in the state of Rio Grande do Sul, Brazil, in 2008 and 2009, based on information from YF epizootic in NHP, to evaluate the distribution of NHP (*Alouatta* spp.) and the vector (*Haemagogus leucocelaenus*) to define risk areas for YF and environmental predictors. The results showed the following variables with the greatest influence on suitability for YF: water vapor pressure (36%), distribution of NHP (32%), maximum wind speed (11%), annual mean rainfall (7%), and maximum temperature in the warmest month (5%).¹⁵ A study was carried out with 683 confirmed cases of YF in humans and 331 cases in NHP, from December 2016 to June 2017, in the southeastern region of Brazil, combining epidemiological, spatial, and genomic data




FIGURE 3. Death probability for age 40 (A) and 60 (B) years according to blood alanine transaminase values (U/L) and creatinine (mg/dL) at hospital admission. Institute of Infectology Emilio Ribas, 2018.




FIGURE 4. Death probability for age 40 (A) and 60 (B) years according to blood aspartate transaminase values (U/L) and creatinine (mg/dL) at hospital admission. Institute of Infectology Emilio Ribas, 2018. This figure appears in color at www.ajtmh.org.

to characterize the transmission of the disease. The analysis showed a positive correlation between the number of cases in humans and in NHP ($R = 0.62$, $P < 0.0001$). Phylogenetic analysis of the virus from 62 confirmed cases of YF (33 in humans and 29 in NHP), the majority coming from the state of Minas Gerais, showed a unique clade, South American I, probably from endemic areas of the country (north and center-west regions) and no reemergence of the lineage that circulated in 2003 in the state of Minas Gerais.¹⁶

The cases were predominately attended in the month of January, and were mainly male, construction professionals, white, and with low schooling. The observed lethality rate was 27.8%. The analysis of cases of YF in Brazil from 1999 to 2009 demonstrated significant seasonality, with 93% of the cases concentrated from November to May, with 30.1% in January. The lethality rate in the country ranged from 25% to 47%.¹⁴ In a sylvatic YF outbreak in the state of São Paulo in 2009, 64.3% of the cases were male and the mean age was 29 years.⁵ An analysis of sylvatic YF cases in Brazil from 1998 to 2002 showed that 81.3% were male and the median age was 26 years.¹⁷

The higher concentration in males reflects greater displacement and exposure to the virus, especially for those working in sylvatic regions. The median age in the present study was higher among patients who died, probably related to a greater probability of disease severity. Most cases presented symptoms of fever, myalgia, nausea, and vomiting. A Brazilian study with YF cases from 1998 to 2002 showed

similar results: fever (94.4%), headache (83.3%), vomiting (75.8%), and jaundice (69.1%).¹⁷ In the present study, the proportion of jaundice was lower (46.5%), and this can be justified by our validation of the jaundice sign by laboratory tests ($TB \geq 2.0$ mg/dL), and also by most of the mild and moderate cases of our sample. Sixty-nine cases reported their YF vaccination status (95.8%), and 3 (4.3%) of those cases were vaccinated at least 10 days before the onset of symptoms. The Brazilian study showed a lower proportion (2.0%) of vaccinated individuals; however, it presented an important portion of ignored information regarding YF vaccination (19.5%). These cases may reflect primary vaccine failure. The attenuated virus YF vaccine, the 17D strain, was developed in 1936. A multicenter clinical trial conducted to evaluate two vaccines derived from strain 17-DD, ARILVAX and YF-VAX, showed an efficacy of 98.6% and 99.3%, respectively, when seroconversion was evaluated 30 days after vaccination.¹⁸ The 17-DD vaccine is produced at Biomanguinhos-Fundação Oswaldo Cruz-RJ, Brazil, and supplies the country and other countries of South and Central America, Africa, and Asia. A randomized clinical trial with 1,087 adults in Rio de Janeiro showed equivalence between the different substrains, 17D and 17-DD. The seroconversion rate was 98% among the seronegative and 90% among the seropositive subjects before the vaccine.¹⁹ In 2013, the WHO concluded that a single dose of the vaccine provided prolonged immunity without the need for a booster dose. Studies were conducted to evaluate the immunity of the vaccine after 10 years, and the results

TABLE 5
Factors associated with death due to yellow fever, Institute of Infectology Emilio Ribas, 2018

Factors associated	OR _{unadjusted} (CI 95%)	P-value	OR _{adjusted} (CI 95%)	P-value
Age (ref: < 42 years)	4.96 (1.57–15.68)	0.006		
Platelets (ref: $\geq 98,000$ cells/mm ³)	4.07 (1.35–12.32)	0.012		
Total bilirubin (ref: ≤ 1.72 mg/dL)	20.19 (4.19–97.38)	< 0.001		
Direct bilirubin (ref: ≤ 1.19 mg/dL)	12.00 (3.08–46.83)	< 0.001		
Aspartate aminotransferase (ref: $\leq 1,841$ U/L)	20.19 (4.19–97.38)	< 0.001	12.92 (1.50–111.37)	0.020
Alanine aminotransferase (ref: $\leq 1,924$ U/L)	5.22 (1.65–16.58)	0.005		
International normalized ratio (ref: ≤ 1.32 seconds)	20.19 (4.19–97.38)	< 0.001		
Urea (ref: ≤ 40 mg/dL)	21.53 (4.44–104.40)	< 0.001		
Creatinine (ref: ≤ 1.2 mg/dL)	109.25 (18.43–647.54)	< 0.001	81.47 (11.33–585.71)	< 0.001
Creatine phosphokinase (ref: ≤ 304 U/L)	7.97 (2.29–27.72)	< 0.001		

OR = odds ratio.

showed that 88% of the vaccinated individuals remained seropositive after this period. However, when stratified by area, 97.6% of vaccinees in endemic areas maintained detectable levels of nourishing antibodies in endemic areas, whereas only 83.7% in non-endemic areas. The change in the WHO's recommendation for YF vaccine has led to intense debates among several groups.²⁰ It is important to emphasize that the effectiveness of the vaccine in mass campaigns is not the same as that in randomized control studies, and may increase primary vaccine failure.

Yellow fever is a disease with a variable clinical spectrum, from asymptomatic cases to critical manifestations. Studies in Africa showed that for 7–12 asymptomatic cases, there was one symptomatic case.²¹ This study evaluated the incidence of YF from data from 11 studies conducted in Africa and South America and estimated the likelihood of clinical manifestations among those infected. The results showed the following: 55% (37–74%) asymptomatic, 33% (13–52%) with moderate clinical manifestations, and 12% (5–26%) critical.²² Considering our cases classified as severe YF (56.9%), there was probably an important proportion of asymptomatic, mild, and moderate cases among the population who were not diagnosed and reported, reflecting a possible lack of information about the real burden of the disease during this public health emergency.

The initial clinical presentation is similar to a nonspecific viral disease, with sudden onset of fever, headache, myalgia, nausea, and vomiting. Following this framework, most patients recover. However, approximately 15% of patients evolve after a short period of remission (hours to 1 day) to a severe condition, with jaundice, hemorrhagic symptoms, and multiple organ failure. The lethality rate for cases with renal and hepatic insufficiency ranges from 20% to 50%,²³ a similar result to our findings (27.8%).

The regression models demonstrated an association between age, ALT, and AST, and creatinine. Hepatic impairment is classically described as a determinant of outcome in YF. Age > 60 years was a significant factor related to death in this series. The higher case-fatality rate for older adults has been previously reported in both dengue²⁴ and YF,^{17,25} and is probably associated with a higher prevalence of comorbidities in this age group, as observed in the case analyzed in the study. A study conducted in Brazil identified AST (> 1,200 IU/L) and jaundice as independent factors associated with higher mortality.¹⁷ A study evaluated 23 cases of YF during the Senegal epidemic in 1965, and when analyzing serum AST levels in patients who died, the mean was at least three times higher than the cases that survived, and twice or greater than the mean of ALT.²⁶ An experimental study evaluated the pathogenicity of YF virus in an animal model, with intraperitoneal inoculation in hamsters, using strains of the sylvatic YF virus of humans. The results indicated that the mortality rate was related to the viral load and age of the animals. Alanine aminotransferase, a more specific marker of hepatic necrosis, showed significantly elevated levels between day 4 and day 6.²⁷ A report of a death from YF of a resident of China who traveled to Angola presented an extensive multilobular necrosis (critical) and hepatitis with panlobular characteristics and confluent hepatic necrosis in a liver biopsy.²⁸

Another study evaluated the histopathological findings of the liver of 53 patients who evolved to death during the occurrence of sylvatic YF, and all cases were confirmed with laboratory

tests. There was a predominance of CD4⁺ T lymphocytes, accompanied by CD8⁺ T lymphocytes, natural killer cells (CD57), macrophages, and antigen-presenting cells (S100). The disproportion between the inflammatory response and the degree of liver damage is probably related to intense apoptosis. Despite this, the immune cellular response plays an important role in the pathogenesis of liver damage observed in YF.²⁹

The impact of renal impairment on the clinical outcome of YF was evaluated in a study conducted in Brazil. In the univariate analysis of risk factors related to death in patients with YF, the value of urea > 100 mg/dL presented a relative risk of 5.77 (1.43–23.22, $P < 0.01$). However, in the multivariate analysis, this variable did not remain significant. It should be noted that the creatinine value was not significant, although it presented lower values among the survivors ($1.3 \times 4.7 P = 0.16$), probably due to the small number of tests available ($n = 20$).¹⁷ In our analysis, creatinine was an independent factor related to death. The value of creatinine is more specific to renal impairment than urea, especially in this analyzed context, where the underlying disease is associated with bleeding. The upper digestive bleeding is a cause of increased urea and could influence this result, regardless of renal function. Another aspect that compromises the value of urea is the influence of liver function on the levels detected, as it is synthesized in the liver and could be decreased by hepatic failure, independently of renal function. In 2018, five cases of YF were reported in international travelers who were infected in Brazil: in São Paulo (1), in Minas Gerais (1), and in Rio de Janeiro (3). Two cases evolved to death, both presenting renal and hepatic insufficiency. Among the survivors, only 1 presented these complications.³⁰

The limitations of the study include the sample size, which made it impossible to analyze a greater number of variables in the regression models. Underreporting of cases can also be a limitation, although the Epidemiology Service of IIER develops an active search daily in the emergency room, inpatient units, and in the laboratory, thus maintaining high sensitivity for the detection of suspected cases of YF. The quality of information may be compromised, especially in cases of hospitalization of critical patients who quickly died. However, the information was collected on a standardized form (EIF) with an interview performed on the patient's admission to the emergency room, and with the case relatives when possible, thus minimizing this bias. The hospital is specialized in infectious diseases, maintaining qualified and trained clinical staff to identify suspected cases of YF.

In conclusion, the reemergence of YF in the state of São Paulo, especially in the metropolitan region of São Paulo, impacted on the organization of patient care in the IIER. The study identified the association between age, hepatic, and renal impairment, evaluated through elevated levels of AST, ALT, and creatinine, as independent factors for death in individuals with YF, which may contribute to the appropriate clinical management of patients with YF in other contexts. The timely identification, reporting, and epidemiological investigation of suspected cases enable pertinent implementation of control measures. It is important to emphasize the need to maintain high vaccine coverage in recommended areas, as well as vaccines for travelers.

Received November 3, 2018. Accepted for publication April 10, 2019.

Published online May 28, 2019.

Acknowledgments: We thank the staff of Epidemiology Service of IIER for their cooperation on collecting the surveillance data. We also thank

the Yellow Fever Group of the IIER, the Adolfo Lutz Institute, and those who contributed to this study.

Authors' addresses: Ana Freitas Ribeiro, Roberta Figueiredo Cavalin, Jamal Muhamad Abdul Hamid Suleiman, Jessica Alves da Costa, Marileide Januaria de Vasconcelos, Ceila Maria Sant'Ana Málaque, and Jaques Sztajnbok, Institute of Infectology Emilio Ribas, São Paulo, Brazil, E-mails: anafribeiro@uol.com.br, roberta.cavalin@usp.br, jamal.suleiman@emilioribas.sp.gov.br, jessicacosta20@hotmail.com, marileide.vasconcelos@emilioribas.sp.gov.br, cmalaque@uol.com.br, and jaques.sztajnbok@gmail.com.

REFERENCES

- Vasconcelos PFC, 2003. Febre amarela. *Rev Soc Bras Med Trop* 36: 275–293.
- World Health Organization, 2016. *Situation Report—Yellow Fever, 28 October 2016*. Geneva, Switzerland: WHO. Available at: <http://apps.who.int/iris/bitstream/10665/250661/1/yellowfeversitrep28Oct16-eng.pdf?ua=1>. Accessed July 15, 2018.
- Secretariat of Health Surveillance, Ministry of Health, Brazil, 2017. *General Coordination of Epidemiology Development in Services. Health Surveillance Guide: Single Volume*, 2nd edition. Brasília, Brazil. Available at: <http://portal.arquivos.saude.gov.br/images/pdf/2017/outubro/06/Volume-Unico-2017.pdf>. Accessed July 20, 2018.
- Secretariat of Health Surveillance, Ministry of Health, Brazil, 2017. *Epidemiological Situation of Yellow Fever*. Brasília, Brazil. Available at: <http://portalms.saude.gov.br/saude-de-a-z/febre-amarela-sintomas-transmissao-e-prevencao/situacao-epidemiologica-dados>. Accessed July 22, 2018.
- Mascheretti M et al., 2013. Yellow fever: reemerging in the state of Sao Paulo, Brazil, 2009. *Rev Saúde Pública* 47: 1–9.
- Secretariat of Health Surveillance, Ministry of Health, Brazil, 2017. *Emergency Operations Center in Public Health on Yellow Fever—Report 43*. Brasília, Brazil. Available at: <http://portal.arquivos.saude.gov.br/images/pdf/2017/junho/02/COES-FEBRE-AMARELA---INFORME-43---Atualiza----o-em-31maio2017.pdf>. Accessed July 25, 2018.
- Secretariat of Health Surveillance, Ministry of Health, Brazil, 2018. *Emergency Operations Center in Public Health on Yellow Fever—Report 26*. Brasília, Brazil. Available at: <http://portal.arquivos2.saude.gov.br/images/pdf/2018/maio/18/Informe-FA-26.pdf>. Accessed July 26, 2018.
- Monath TP et al., 1980. Yellow fever in the Gambia, 1978–1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. *Am J Trop Med Hyg* 29: 912–928.
- Vasconcelos PF, Rodrigues SG, Degallier N, Moraes MA, da Rosa JF, da Rosa ES, Mondet B, Barros VL, da Rosa AP, 1997. An epidemic of sylvatic yellow fever in the southeast region of Maranhao State, Brazil, 1993–1994: epidemiologic and entomologic findings. *Am J Trop Med Hyg* 57: 132–137.
- Domingo C, Patel P, Yillah J, Weidmann M, Méndez JA, Nakouné ER, Niedriga M, 2012. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. *J Clin Microbiol* 50: 4054–4060.
- Bae HG, Nitsche A, Teichmann A, Biel SS, Niedrig M, 2003. Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay. *J Virol Methods* 110: 185–191.
- Secretary of State for Health of Minas Gerais, 2018. *Flowchart for Yellow Fever Care*. Minas Gerais, Brazil. Available at: http://www.saude.mg.gov.br/images/documentos/Fluxograma%20de%20Atendimento%20-%20Febre%20Amarela%20V02_03_2018.pdf. Accessed July 29, 2018.
- Sanchez OS, 2003. O processo de ocupação em áreas de proteção aos mananciais: conflito com a lei e realidade social na Região Metropolitana de São Paulo. Martins RC, Valencio NFLS, eds. *Uso e Gestão dos Recursos Hídricos no Brasil*. São Carlos, Brazil: RiMa, 293. Available at: http://www.teses.usp.br/teses/disponiveis/18/18139/tde-17112016-120909/publico/Dissert_Sanchez_PatriciaS_corrigido.pdf. Accessed July 20, 2018.
- Costa ZGA, Romano APM, Elkoury ANM, Flannery B, 2011. Evolução histórica da vigilância epidemiológica e do controle da febre amarela no Brasil. *Rev Pan-Amaz Saude* 2: 11–26.
- de Almeida MAB, dos Santos E, Cardoso JC, Silva LG, Rabelo RM, Bicca-Marques JC, 2018. Predicting yellow fever through species distribution modeling of virus, vector, and monkeys. *EcoHealth* 16: 95–108.
- Faria NR et al., 2018. Genomic and epidemiological monitoring of yellow fever virus transmission potential. *Science* 361: 894–899.
- Taboi SH, Costa ZGA, Vasconcelos PFC, Hatch D, 2007. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998–2002. *Trans R Soc Trop Med Hyg* 101: 169–175.
- Monath TP et al., 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. *Am J Trop Med Hyg* 66: 533–541.
- Camacho LAB, Freire MS, Leal MLF, de Aguiar SG, do Nascimento JP, Iguchi T, Lozana JA, Farias RHG; Collaborative Group for the Study of Yellow Fever Vaccines, 2004. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. *Rev Saúde Pública* 38: 671–678.
- Amanna IJ, Slifka MK, 2016. Questions regarding the safety and duration of immunity following live yellow fever vaccination. *Expert Rev Vaccines* 15: 1519–1533.
- Monath TP, Vasconcelos PFC, 2015. Yellow fever. *J Clin Virol* 64: 160–173.
- Monath TP, Gershman M, Staples JE, Barrett ADT, 2013. Yellow fever vaccine. Plotkin SA, Orenstein WA, Offitt PA, eds. *Vaccines*, 6th edition. Edinburgh, Scotland: Elsevier/Saunders, 870–968.
- Tesh RB, Guzman H, da Rosa AP, Vasconcelos PFC, Dias LB, Bunnell JE, Zhang H, Xiao SY, 2001. Experimental yellow fever virus infection in the golden hamster (*Mesocricetus auratus*). I. Virologic, biochemical and immunologic studies. *J Infect Dis* 183: 1431–1436.
- Moraes GH, Duarte EF, Duarte EC, 2013. Determinants of mortality from severe dengue in Brazil: a population-based case-control study. *Am J Trop Med Hyg* 88: 670–676.
- Hanson H, 1929. Observations on the age and sex incidence of deaths and recoveries in the yellow fever epidemic in the department of Lambayeque, Peru, in 1921. *Am J Trop Med* 9: 233–239.
- Oudart JL, Rey M, 1970. Proteinuria, proteinaemia, and serum-transaminase activity in 23 confirmed cases of yellow fever [article in French]. *Bull World Health Organ*. 42: 95–102.
- Chen Z et al., 2016. A fatal yellow fever virus infection in China: descriptions and lessons. *Emerg Microbes Infect* 5: 1–8.
- Quaresma JAS, Barros VLRS, Pagliari C, Fernandes ER Jr., Andrade HF, Vasconcelos PFC, Duarte MI, 2007. Hepatocyte lesions and cellular immune response in yellow fever infection. *Trans R Soc Trop Med Hyg* 101: 161–168.
- Hamer DH et al., 2018. Fatal yellow fever in travelers to Brazil, 2018. *MMWR Morb Mortal Wkly Rep* 67: 340–341.
- Johansson MA, Vasconcelos PFC, Staples JE, 2014. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. *Trans R Soc Trop Med Hyg* 108: 482–487.